COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s): CSCI

Healthcare Biotechnology

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

TSX:CSCI - Post by User

COSCIENS Biopharma Inc > Limitations according to one article:

<< Previous

Bullboard Posts

Next >>

Post by prophetoffactzon Aug 24, 2024 9:32am

93 Views

Post# 36194540

Limitations according to one article:

Macimorelin is CSCI's test.
Are these issues solvable?

"The other tests suggested by guidelines are the glucagon stimulation test (GST) and the macimorelin test [3]. Macimorelin is a synthetic GH secretagog (GHS) [7] that has the advantage to be orally administered, with few side effects [8]. Unfortunately, very high cost and the potential drug-to-drug interactions limit the use of the test. Moreover, the announcement in August 2022 that macimorelin should be temporarily discontinued in the commercial market of US makes this test less used in clinical practice..."

Once upon a time: the glucagon stimulation test in diagnosing adult GH deficiency - PMC (nih.gov)

<< Previous

Bullboard Posts

Next >>

How to decrease sector risk by owning hundreds of mineral assets